Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress
FLORHAM PARK, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity” or the “Company”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company’s Founder and CEO, Dr. Robert Hariri, M.D., Ph.D., will present the keynote lecture at the Society for Brain Mapping and Therapeutics (SBMT) Annual World Congress on March 16, 2024.
- FLORHAM PARK, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity” or the “Company”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company’s Founder and CEO, Dr. Robert Hariri, M.D., Ph.D., will present the keynote lecture at the Society for Brain Mapping and Therapeutics (SBMT) Annual World Congress on March 16, 2024.
- Dr. Hariri’s keynote, titled, “Future of Cell and Immunotherapy – Cancer to Neurodegenerative Disorders,” will address cellular immunotherapy’s broad applications beyond cancer, including its potential use in neuroinflammatory and degenerative conditions, such as multiple sclerosis and Parkinson’s disease.
- Celularity is advancing innovative cellular therapeutics to treat a range of diseases, including neurologic diseases from brain cancer to age-related cognitive decline.
- SBMT’s 21st Annual World Congress will take place in Los Angeles, Calif., on March 14 through 17, 2024.